Last update Sept. 15, 2026

Bacterial Lysates

Compatible

Safe product and/or breastfeeding is the best option.

Extracts from bacterial lysates used for the prevention of recurrent infections, asthma and other conditions. Usually administered orally (also sublingually or nasally).

As of the date of the last update, we found no published data on its excretion in breast milk.

It is unlikely that it passes into breast milk and, even if it did, it is likely to be broken down in the infant’s gut.

Furthermore, they are non-toxic and have no side effects.

There is controversy and very little evidence regarding the efficacy of these products in the prevention or treatment of recurrent respiratory or urinary tract infections. (Huttner 2017, O'Brien 2016, Mobley 2015, Murcia Salud 2015, Tang 2015, Pan 2015, Lenk 2009)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Bacterial Lysates is also known as


Group

Bacterial Lysates belongs to this group or family:

Tradenames

Main tradenames from several countries containing Bacterial Lysates in its composition:

References

  1. Zhu LL, Wang YH, Feng JH, Zhou Q. Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics. Drug Des Devel Ther. 2024 Oct 1;18:4387-4399. Abstract Full text (link to original source)
  2. Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017 Abstract
  3. O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ. Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiol Spectr. 2016 Abstract
  4. Pan L, Jiang XG, Guo J, Tian Y, Liu CT. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. J Clin Pharmacol. 2015 Abstract
  5. Murcia Salud. ¿Existe indicación de vacunas orales para el tratamiento de infecciones urinarias recurrentes? Sumarios de evidencia. 2015 Full text (link to original source) Full text (in our servers)
  6. Mobley HL, Alteri CJ. Development of a Vaccine against Escherichia coli Urinary Tract Infections. Pathogens. 2015 Abstract
  7. Tang H, Fang Z, Saborío GP, Xiu Q. Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease. Lung. 2015 Abstract
  8. Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Recurrent urinary tract infections in women. Int Urogynecol J. 2015 Abstract
  9. Lenk VS, Dorsch B. [Vaccinations in recurrent urinary tract infections--an observation study relating to health economy]. Aktuelle Urol. 2009 Abstract

Total visits

16,887

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM